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Abstract 
This paper examines the experimental foundations of reports in the literature on mitochondrial diseases involving Complexes I and I| 
of the respiratory chain. Many of the reports may be questioned on the basis of the assay conditions used which disregard established 
knowledge of the precautions required for valid activity measurements. In addition, some findings are open to question because of the 
experimental material chosen for the study, such as the measurement of NADH oxidase activity in platelets in Parkinson's disease, which 
affects selectively the dopamine neurons, or the use of autopsy material stored for prolonged periods during which post-mortem changes 
may have occurred. Deficiencies claimed to involve several components of the respiratory chain may reflect indirect effects, such as 
defects in the synthesis of iron-sulfur clusters or in the availability of iron, rather than mutations in the genes coding for the deficient 
enzymes. Nevertheless, there are a few instances reported of Complex II deficiency free from such criticisms. As to Complex I, idiopathic 
Parkinsonism appears to involve a documentable decline in the activity of this enzyme. Using the model system provided by 
N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP), which produces biochemical, pharmacological, nd clinical syndromes closely 
resembling Parkinsonism, the etiology of the disease is examined. 
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1. Introduction 
This paper concentrates on diseases and drugs affecting 
selectively the succinate and NADH dehydrogenases of the 
mitochondrial respiratory chain. We will avoid a detailed 
discussion of the genetic basis of diseases, as several other 
contributors, notably Drs. Walker and Schon, will cover 
this aspect. Further, we will only briefly touch on disease 
entities where several components of the respiratory chain 
appear deficient, since they may represent mutations in 
some component other than the enzyme in question. 
2. Multiple deficiencies 
Desnuelle et al. [1] reported some 5 years ago a multi- 
ple respiratory chain complex deficiency in a patient with 
progressive neurological disease, including muscle weak- 
ness and encephalopathy. Table 1 illustrates the point we 
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would like to make, namely that Complexes I, II, and III 
showed a severe deficiency, while Complex IV was nor- 
mal. Remembering that Complex IV is the only one lack- 
ing Fe-S clusters, the similarity to the picture seen in 
skeletal muscle mitochondria of Fe-deficient rats is strik- 
ing and suggests that the defect in the patient may reflect a 
lack of available iron or an impaired machinery for Fe-S 
cluster synthesis. Alternatively, iron concentration may 
exert control over the synthesis of specific protein subunits 
at the level of transcription/translation. I  either case, 
decreased assembly of Complexes I, II, and III would 
result. 
The former explanation was also suggested by Hall et 
al. [2] based on their later studies of biopsy samples from a 
patient with marked exercise intolerance and myoglobin- 
uria. They noted severe decreases in the levels of mito- 
chondrial enzymes assayed that contained Fe-S centers 
(succinate and NADH dehydrogenases, Complex III, 
aconitase) as well as in rhodanase, but not in cytochrome 
oxidase. The data clearly point to Fe-S as a common 
denominator in the decreased assembly of respiratory com- 
plexes or in the formation of unstable forms which are 
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Table 1 
Levels of mitochondrial ctivities in a human myopathy and in Fe-defi- 
cient rats 
Enzyme Activity (% of control) 
human myopathy a Fe-deficient rats 
Inner membrane 
(1) Complex I 18 23 
(2) Complex II 15 16 
(3) Complex III 19 - 
(4) Complex IV 100 100 
(5) ETF-dehydrogenase b _ ~ 100 
Matrix 
(1) Aconitase - 22 
(i) Non-activated 
(ii) Activated - 43 
(2) Malate dehydrogenase - 100 
(3) Fumerase - 100 
a From Desnuelle t al. [1]. 
b By Western blotting. 
subject o degradation. It should be noted that although the 
amounts of Complexes I and II assembled in Fe-deficient 
rat membranes are much lower than in controls, only intact 
and fully active complexes are present. No aberrant forms 
or free subunits are detectable [3]. 
3. Succinate dehydrogenase 
Complex II is structurally far simpler than Complex I 
and better characterized. It is comprised of four subunits 
(Fig. 1; adapted from Ref. [4]). The hydrophilic domain 
comprises a flavoprotein (Fp) with a histidyl-FAD moiety 
and an iron-sulfur subunit (Ip) harboring the three clusters 
[2Fe-2S] 2+'1 +, [4Fe-4S] 2+: ÷, and [3Fe-4S] l +.o. Two mem- 





Cu.s and Ca4 
Fig. 1. Structure of Complex II. 
Table 2 
Status of the cloning of mammalian complex II
Subunit Cloned Total Amino Acids References 
mature protein presequence 
Human heart Fp + 621 43 [5] 
Beef heart Fp + 621 44 [5,6] 
Human liver Ip + 252 n.c. [7] 
Beef heart Ip + 252 28 or 33 unpublished 
Human heart CII_3 + n.c. n .c .  unpublished 
Beef heart C ii-3 + 140 29 unpublished 
Human C 1[-4 . . . .  
Beef heart C u-4 + n.c. n .c .  unpublished 
n.c., not completed. 
for the catalytic subunits and provide the binding sites for 
ubiquinone. All four subunits are nuclear encoded and 
must therefore be imported into the mitochondrion. Thus 
far, beef Fp, Ip, and C l 1_3, together with human Fp and Ip, 
have been cloned and the sequences of the precursor forms 
determined (Table 2). 
Reports in the literature of Complex II deficiency often 
suffer from shortcomings in the assay of the enzyme, 
which render the significance uncertain. For example, (i) 
the enzyme was not preactivated to remove the variable 
amounts of tightly-bound and inhibitory oxaloacetate al- 
most certainly present. (ii) In assays using dyes like tetra- 
zolium, dichlorophenol indophenol, or cytochrome c, none 
of which react directly with the enzyme, only a fraction of 
the activity is measured. Deficiency argued on the basis of 
succinate-cytochrome c, rather than succinate-ubiquinone 
reductase activity, gives little consideration as to what 
component is actually rate limiting. (iii) No-one has yet 
determined the turnover number of Complex II in those 
membranes where activity is low to see whether the com- 
plex is defective or just present in lower amounts. 
The mutational rate of Complex II is far lower than 
other complexes because mtDNA is not involved. More- 
over, in contrast o Complex I, which reacts with a multi- 
tude of drugs and toxic substances (see below), SDH has 
not been shown to be inhibited by such agents other than 
carboxins. These are fungicides at one time widely sprayed 
on Canadian wheat. They represented a major environmen- 
tal hazard because of their extremely high affinity for 
mammalian succinate dehydrogenase. 
A survey of the literature has shown a single report, by 
Rivner and coworkers [8], in which a selective deficiency 
of succinate dehydrogenase was claimed in a patient with 
Kearns-Sayre syndrome. However, activity data were ob- 
tained using inappropriate assay conditions (see above) 
and the Western blots, in our view, lacked proper controls. 
Further, the authors failed to assay Complex III separately. 
In contrast, recent collaborative work by Dr. Turnbull in 
Newcastle-upon-Tyne and Dr. Ackrell of this laboratory 
has uncovered such a case (unpublished ata). Two female 
patients have presented with progressive unsteadiness, 
headaches, and bilateral optic atrophy. Cursory examina- 
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Fig. 2. Western Blots of muscle mitochondria from patients with Com- 
plex II aberration, loaded at constant citrate synthetase activity. 
tion of mitochondria from both muscle biopsy material and 
platelets has indicated a major decrease in the succinate- 
ubiquinone activity of Complex II (40 to 50% of control) 
following preactivation of the enzyme with succinate to 
remove oxaloacetate. The activities of Complexes I, III, 
and IV, and matrix aconitase were normal. Western blot- 
ting with anti-beef Fp, Ip, and C ,1-3 antibodies howed, 
surprisingly, a significant increase in the level of Fp 
subunit of the patients (labelled I and II) compared to 
controls (C), but not in the other subunits (Fig. 2), i.e., 
there appears to be a selective aberration in the synthesis 
and assembly of Fp. 
4. NADH dehydrogenase 
While the number of reports involving diseases with a 
deficiency of Complex I (NADH dehydrogenase) is much 
greater than those involving specific defects of succinate 
dehydrogenase, the molecular basis has been far more 
difficult to ascertain. Complex I is the most complex of 
mitochondrial respiratory enzymes, with around 40 sub- 
units, some of which are nuclear coded, some coded by 
mDNA, and only a few of the subunits react with antibod- 
ies generated to isolated Complex I. Moreover, it has the 
highest turnover number of any mitochondrial oxidizing 
enzyme but is also the most difficult to assay. Thus, the 
use of inappropriate assays, like the NADH-cytochrome c 
reductase assay, measures but a small and uncertain frac- 
tion of the activity in mitochondria, frozen or not, or in 
muscle or brain cell homogenates. Even the Ql reductase 
assay measures less than the full activity of the primary 
dehydrogenase [9]. 
A further complication is that the enzyme is much less 
stable than succinate dehydrogenase and progressively loses 
activity on storage in the frozen state. Yet, in an oft-quoted 
study [11], frozen samples were analyzed after 6 to 7 years 
storage. More importantly, the enzyme is subject o prote- 
olysis if the period between death and freezing is pro- 
longed - as was the case in some literature reports where 
over 10 h elapsed before autopsy and freezing of the 
sample [10]. The use of controls preserved without freez- 
ing for comparable time [l 1] in no way corrects for this, 
because it cannot be assumed that proteolytic destruction 
will proceed at identical rates in each patient after death, 
It is not surprising, therefore, that presumably unam- 
biguous methods gave conflicting results in the hands of 
different workers. Thus, the laboratory of Mizuno and 
Ozawa [10] found a decrease in the quantities of certain 
Complex I subunits in post-mortem nigrostrial samples of 
Parkinsonian patients, while Schapira and colleagues 
[11,12] reported decreased NADH-QI reductase activity 
without a change in the staining intensity of Complex I
subunits detectable by immunoblotting. The discrepancy 
may be due to the use of control patients being younger 
than the Parkinson patients in one of these studies [10]. 
Several aboratories noted that a 5 kb deletion in mtDNA 
(which includes genes for 7 of the 40 peptides of the 
enzyme), as commonly seen in several neuromuscular 
diseases, is part of the normal aging process [11-13]. Only 
in aged-matched patients, therefore, will the subunit band 
pattern on gels be comparable to those of the control. 
Three major types of mitochondrial encephalomy- 
opathies have been reported to be accompanied by various 
degrees of decreased activity of NADH dehydrogenase 
[14]. This sometimes is reflected in alterations of the 
subunits present, sometimes not. There may also be ac- 
companying decreases in the activities of the other com- 
plexes of the respiratory chain. The literature is confused 
and often contradictory, which is not surprising in view of 
the factors mentioned previously, in particular the frequent 
use of enzyme assays of doubtful validity. 
The most clear-cut example of a disease accompanied 
by a selective decline in NADH dehydrogenase activity is 
idiopathic Parkinsonism, as reported by Parker et al. [15], 
Mizuno et al. [10], and Schapira's group [16]. The data of 
the latter investigators are probably the most persuasive, 
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Fig. 3. Conversion of a meperidine analog to MPTP. 
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Fig. 4. Schematic representation of the events from the bioactivation f
MPTP by glial monoamine oxidase B to the blockade of mitochondrial 
respiration. 
since relatively fresh post-mortem aterial and valid as- 
says, at least for NADH-Q reductase activity, were used. 
Since Parkinson's disease involves selective destruction of 
nigrostriatal neurons, one would not expect its signs to be 
manifest in platelet and muscle biopsy samples, although 
some investigators ubstituted these for striatal cells be- 
cause of their ready availability. 
5. Idiopathic and MPTP-induced Parkinsonism 
The notion that Complex I deficiency may be related to 
the primary disease process in Parkinsonism or, for that 
matter, is the primary etiology thereof arose because of the 
striking similarity in the clinical picture, the histopathol- 
ogy, and response to L-DOPA of idiopathic Parkinsonisms 
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Fig. 5. Site of action of rotenone, piericidin A, and MPP + in the 
respiratory chain. 
and of the MPTP-induced Parkinsonian syndrome in hu- 
mans and some other mammals. This remains very much a 
viable hypothesis, despite the fact that the weight of 
evidence suggests that oxyradical damage due to the over- 
production MAO B, coupled with a predisposition to the 
disease, rather than an obvious genetic anomaly or endoge- 
nous or exogenous toxins, is the primary cause of idio- 
pathic Parkinsonism. It is thus of importance to review 
current knowledge of how the oxidation products of MPTP 
inactivate Complex I. 
It has been 11 years since Langston and colleagues [ 17] 
first recognized that the sudden onset of Parkinsonism-like 
symptoms in a group of relatively young persons was 
caused by the presence of MPTP in preparations of an 
illicit heroin substitute closely related to the drug meperi- 
dine (Fig. 3). Soon on the heels of this announcement, 
three laboratories howed that MPTP produced similar 
symptoms in subhuman primates and mice [18-20]. By 
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Fig. 6. The concentration dependence of the inhibition of NADH oxidase by MPP + and some of its analogs is time-dependent. ETP (0.8 mg/ml) were 
preincubated with the analog at 25°C for various times, then diluted to 20 /xg/ml in the cuvette containing the same concentration f inhibitor, and 
assayed at 30°C as described under Experimental Procedures (method 2). (A) MPP + for 5 min. (O) or 156 min (0). (B) 4'-t-Butyl-MPP +for 5 min. 
(C)), 12 min (Q), or 2 l0 min. ( zx ). (C) 4'-heptyl-MPP ÷ for 5 min. ((3) or 60 min ( zx ). (D) 4-phenylpyridine for 5 min. ((3), 10 min. ( [] ), or 60 min ( zx ). 
The control activity was 3.07 + 0.19 #mol/min per mg protein. From [30]. 
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Fig. 7. Concentration dependence of the inhibition of NADH oxidase by 4'-alkyl-MPP ÷ analogs in the presence of TPB-. The preincubation (5 min) and 
assay are described under Experimental procedures (method 1). TPB- (10 /xM) was added immediately before the MPP + analogs which were 
4'-methyl-MPP ÷ (O), 4'-propyl-MPP ÷ (O), 4'-pentyl-MPP ÷ (• ) ,  and 4'-heptyl-MPP + (/,). The activity obtained after adding a second aliquot of TPB- 
in flight is shown in D (zx). From [11]. 
1984 suggestive vidence appeared that MPTP had to be 
metabolized to the 4-e oxidation product, MPP ÷, in the 
brain in order to express its potential neurotoxic effect 
[21]. Our laboratory, in collaboration with Castagnoli's, 
then demonstrated that both monoamine oxidase (MAO) A 
and B oxidized MPTP to MPP + [22], but for kinetic 
reasons glial MAO B was the enzyme primarily responsi- 
ble for the toxification [23,24]. Among the numerous other 
neurotoxic MPTP analogs oxidized by MAO, the B en- 
zyme is responsible for the bioactivation of MPTP in vitro 
and in vivo, the A and B forms for the bioactivation of 
4'-methyl-MPTP, and the A enzyme for the bioactivation 
of 4'-ethyl-MPTP [25,26]. 
Then, Javitch and colleagues resolved the next step in 
this curious set of events (Fig. 4), namely that the synaptic 
dopamine carrier collects the MPP ÷ formed in the glia 
cells and pumps it into the dopamine neuron: this is the 
main reason why nigrostriatal cells are the primary victims 
of exposure to MPTP. We then elucidated the next step: 
concentration of MPP ÷, up to thousands of times the 
cytoplasmic concentration, into the matrix of mitochondria 
[27,28], in response to the electrochemical gradient across 
the inner membrane. MPP + then blocks the mitochondrial 
oxidation of NAD÷-linked substrates, as first shown by 
Nicklas et al. [29], who proposed that the blockade occurs 
at the 'rotenone site', i.e., at the junction of Complex I and 
the Q pool (Fig. 5). 
There is yet another barrier to overcome before MPP ÷ 
and its analogs reach the inhibition site: penetration into 
the membrane (Fig. 6). With positively charged and rela- 
tively hydrophilic MPP ÷ derivatives the rate of develop- 
ment of the inhibition in an inverted inner membrane 
preparation (ETP) is a very slow process, as seen in Fig. 
6A and B for MPP + and 4'-t-butyl-MPP ÷, respectively, so 
that the process takes several hours to reach completion. In 
contrast, the much more hydrophobic 4'-heptyl-MPP ÷pen- 
etrates the membrane rapidly, so that maximal inhibition is 
reached in 2 to 3 min (Fig. 6C). This is even more evident 
with the very hydrophobic and uncharged 4-phenylpyri- 
dine (Fig. 6D). 
If we include the tetraphenylboron anion (TPB-), which 
forms very tight ion pairs with positively charged MPP ÷ 
analogs [31-33], the inhibition of NADH oxidation by 
relatively hydrophilic MPP ÷ analogs develops almost in- 
stantaneously, as seen in Fig. 7 for 4'-methyl MPP ÷ (A), 
4'-propyl-MPP ÷ (B), and 4'-pentyl-MPP ÷ (C). Moreover, 
the IC50 value is lowered about 5-fold and the titration 
curves assume sigmoidal characteristics. With the more 
hydrophobic MPP + analogs TPB- does not potentiate the 
inhibition; in fact it increases the IC50 by competing with a 
hydrophobic binding site on the membrane. 
The sigmoidal titration curves seen here are reminiscent 
of our observations of 25 years ago with rotenone and 
piericidin A, which also gave sigmoidal titration in intact 
inner membrane preparations, but normal hyperbolic ones 
in mercurial-treated ones and in Complex I preparations. In
the latter case this was due to the well-documented prepar- 
ative damage incurred during isolation of the Complex I
[34]. We interpreted this as suggesting that two binding 
sites are involved in the inhibition by rotenone and pieri- 
cidin A, both of which contribute to the inhibition, but to 
unequal extents. 
The observation seen in this figure and others shown 
below suggest hat two sites are involved in the inhibition 
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by MPP + analogs as well. Fig. 8 visualizes our hypothesis 
of these events. It is postulated that one of the two 
inhibition sites (A) is readily accessible to hydrophilic 
compounds, such as MPP +, but occupation of this site 
yields only 35-40% maximal inhibition. 
The other (B) is buried in the hydrophobic milieu of the 
membrane. Its occupation also yields less than 50% inhibi- 
tion, so that both sites have to be filled for complete 
inhibition [30]. 
This visualization is based on several observations. 
4'-phenyl-pyridine (the demethylated form of MPP+), be- 
ing neutral and hydrophobic, readily penetrates the mem- 
brane and occupies site B, and it can, of course, also 
readily enter the exposed, external binding site A. Hence, 
the inhibition develops rapidly and completely (Fig. 4D). 
With MPP + part of the inhibition develops rapidly (about 
35%), the rest requires hours (Fig. 6A). But, if TPB- is 
added, complete inhibition is reached within 1 to 2 min, 
because it neutralizes the charge and renders the inhibitor 
readily available to penetrate the membrane. Note, that 
TPB- acts catalytically: it merely carries the inhibitor into 
the membrane, then disassociates and leaves. 
Returning to Fig. 7D, it shows the titration of the 
NADH oxidase activity in an ETP preparation with 4'- 
heptyl-MPP + in the presence of 10 /zM TPB-. Note that 
in this case the TPB- concentration exceeded that of the 
inhibitor. The curve marked with black squares hows that 
the inhibition under these conditions levels off at 35% and 
only when the concentration of the added inhibitor ap- 
proaches that of the TPB- present is maximal inhibition 





Fig. 8. Hypothetical scheme for two MPP + inhibitor sites in NADH-Q 
oxidoreductase in membrane preparation. From [30]. 
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Fig. 9. Inhibition of NADH oxidation and the simultaneous measurements 
of the accumulation of 4'-heptyl-MPP + into ETP. The polargraphic 
chamber thermostatted at 25 ° C contained 3 ml total volume with 70 /zg 
of ETP protein/ml. The tracing which starts in the upper left corner 
measured oxygen uptake and that which starts in the lower left corner 
voltage output by the ion-selective electrode. The total uptake represents 
5.7/xM 4'-heptyl-MPP +. Unpublished ata of Murphy et al. [42]. 
second 10 /zM aliquot of TPB- (open triangles), the 
inhibition falls to about 35%. We interpret his to suggest 
that when excess TPB- is present, only the external 
inhibition site is occupied, because TPB- successfully 
competes with a putative anionic binding group at the 
hydropic site B; thus the latter is not completely occupied. 
This behavior is even more evident with the exceedingly 
hydrophobic 4'-decyl-MPP + analog. 
A possible clue to the nature of the groups involved in 
binding MPP + at these two sites come from a study of the 
pH dependence of the inhibition of MPP + in the presence 
of 10 /zM TPB- (Fig. 9). The dotted lines indicate slopes 
of + 1 and 0 used to obtain the pK values by the method 
of Dixon [35]. The pK values derived are 6.8, 7.6, and 
8.4. Open and solid circles represent two separate xperi- 
ments. The inflection points indicate the participation of 
two ionizable groups in binding the inhibitor to the free 
enzyme (convex bends) and one in the enzyme-inhibitor 
complex (concave bend). Possible candidates in the free 
enzyme might be an imidazole group for the pK a value of 
~ 6.8 and a thiol group with a pK a value of ~ 8.4. 
Binding of the positively charged inhibitor might modify 
the pK a of one of these groups to ~ 7.6 in the enzyme-in- 
hibitor complex. This putative -SH group was already 
postulated in early studies with rotenone and piericidin, 
where it was shown the treatment of ETP with mercurials 
abolishes one of the two binding sites, resulting in incom- 
plete inhibition by these agents, as is also seen in Complex 
I preparations [34]. The -SH group may be in the internal, 
hydrophobic site B, because in Complex I preparations 
MPP + inhibition is always only partial, regardless of the 
length of the incubation and TPB-, which facilitates pene- 
tration into the hydrophobic site, has no effect. 
In the foregoing discussion it is assumed that MPP + 
and its analog bind at the same 'sites' or in the same 
T.P. Singer et al. / Biochimica et Biophysica Acta 1271 (1995) 211-219 217 
vicinity as rotenone, piericidin A, and barbiturates, as 
proposed by Nicklas et al. [29]. The serendipitous finding 
that 4'-alkyl-MPP + analogs are much more effective in- 
hibitors of NADH oxidation than MPP + with an ICs0 
values of ~ 2 /~M for 4'-decyl-MPP + [36], for instance, 
permitted direct examination of this question. Although 
these ICs0 values where still several orders of magnitude 
higher than the corresponding ones for piericidin A and 
rotenone, they nevertheless permitted the demonstration 
that prior treatment of an inner membrane preparation with 
suitable 4'-alkyl-MPP + analogs prevented both the binding 
of piericidin and rotenone to the inhibition site and the 
resulting inhibition [37]. It seems likely, therefore, that at 
least one of the two binding sites for MPP + and its 
analogs is in the region where piericidin A, rotenone, and 
barbiturates bind and thereby interrupt electron flux to Q. 
Just how the diversity of inhibitors that act at this site [38] 
bring about the same of NADH dehydrogenase to the 
respiratory chain, is not known but the hypothesis [39] that 
compounds which combine at the rotenone site may bring 
about a conformation change unfavorable for electron flux, 
has considerable merit. 
The development of ion-sensitive lectrodes elective 
for MPP + or one of its charged analogs [40,41] permitted 
the direct measurement of the uptake of MPP + derivatives 
into mitochondria and, very recently, their penetration i to 
the inner membrane [42]. Using highly hydrophobic MPP + 
analogs, electrodes capable of measuring uptake in the low 
micromolar ange with great accuracy have been con- 
structed. An example is seen in Fig. 10, which demon- 
strates that uptake of 4'-heptyl-MPP + into an inverted 
inner membrane (ETP) is very rapid, reaching equilibrium 
within the dead time of the recorder. In contrast, the 
development of the inhibition of NADH oxidation moni- 
tored concurrently with an 0 2 electrode in the same vessel, 
takes about 3 min to reach equilibrium. The time depen- 
dence may reflect the diffusion of the inhibitor within the 
membrane or perhaps the time required for proper orienta- 
tO [aM 4'-hcptyI-MPP* 
~ s 
I0 mVl~120 gM 02 ~ \  \ \ \ \ \ \ \ ~ ~ -- 4.3 ~tM 4'-heptyl-MPP* in solution 






Uninbibit~l rate = 0.58 ~mol/mg.mhs 
Inhibited rate = 0.055 ttmol/mg.min (atk~ 3rain) 
Fig. 10. 
tion within the hydrophobic pocket for binding to the 
inhibition site. 
6. Oxygen radicals and Parkinson's disease 
The hypothesis that the underlying cause of Parkinson- 
ism is 'oxidative stress,' i.e., damage due to excessive 
formation of H20 2 and of toxic oxygen radicals has had 
many vocal supporters over the years [43]. Perhaps the 
simplest, though not the only, variant of this hypothesis i  
that the increase in the number of glia cells as part of the 
normal aging process leads to increased MAO B produc- 
tion [44] and, although superoxide dismutase has also been 
reported to increase with age [45], a severe imbalance 
between oxyradical formation and protection against it 
develops gradually. Excessive oxidation of dopamine, the 
main substrate of MAO B in the striatum, leads to deple- 
tion of this neurotransmitter, as well as increased H20 2 
and oxyradical generation [46]. Jenner et al. [47] and 
Dexter et al. [48] presented evidence for increased lipid 
peroxidation i  the nigrostriatum of Parkinsonian patients. 
Although the data are subject o question, since the analy- 
ses were carried out on samples obtained many hours after 
death and thus post-mortem changes cannot be ruled out, 
they are good qualitative indications of increased free 
radical damage. 
The alternative hypothesis of the etiology of idiopathic 
Parkinsonism is that either some environmental gent or an 
endogenous substance, which may be related to MPTP, is 
responsible for the acceleration of the programmed death 
of dopaminagic neurons. Jenner et al. [47] attempted to 
reconcile these two hypothesis by suggesting that the 
putative toxin may generate free radicals, causing selective 
impairment of Complex I, lipid peroxidation, and cell 
death. There is scant evidence, however, that MPP+-like 
compounds generate free radicals in vivo, nor is it neces- 
sary to postulate such a mechanism, since MPP + and its 
congeners block NADH oxidation and this leads directly to 
death of the dopamine neurons. For a discussion of the 
evidence for and against this hypothesis the reader is 
referred to a recent review of one of the authors [49]. 
Although the weight of evidence points to some role of 
oxyradical damage in the development of Parkinsonism 
and there is no doubt that Complex I is particularly 
sensitive damage by free radicals [50], the reason why 
persons who develop Parkinsonism at a much earlier age 
than apoptosis of the dopamine neurons would account for 
in the population at large, remains unclear. 
There is one aspect of the problem, however, which we 
would like to comment on: the question of the sites of the 
oxyradical generation in the respiratory chain. The 
widely-held belief that Complex I is the main site of the 
generation of superoxide and of the oxyradical responsible 
for lipid peroxidation arose as a result of the reports by 
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Fig. l 1. Inhibition of NADH oxidase and 02 production i duced by specifically bound retonone. Rotenone was added to ETP (3 mg protein/ml) followed 
by 0.2 mM NADH and incubated on ice for 10 min. The samples were chilled and BSA was added to 2% (w/v) concentration. After 1 h on ice, tubes 
were centrifuged at146000 X g for 20 min. The pellets were resuspended in 1 ml 0.05 M phosphate buffer (pH 7.4) containing 2% BSA and left on ice 
for 2 h before centrifuging again. The pellets were resuspended in buffer to the original volume. Aliquots were assayed for NADH oxidase activity and 
adrenochrome formation. From [56]. 
Turrens and Boveris [51] and by Minakami and colleagues 
[52,56]. This idea was reinforced by the later finding [54] 
that MPP ÷, like rotenone and amytal, greatly increases 
lipid peroxidation and superoxide formation in submito- 
chondrial particles from heart. 
The importance of these reports becomes evident if one 
considers the fact that Complex I is the target of MPP + 
and its neurotoxic analogs. Thus, by blocking electron 
Inhibition of NADH Oxidose, 02"- Production and Molondialdehyde 
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Fig. 12. NADH oxidase inhibition, 02 production and malondialdehyde 
formation induced by piericidin A. Piericidin A was incubated with ETP 
and the non-specifically bound inhibitor removed as described for rotenone 
in Fig. 4. The washed ETP were assayed for NADH oxidase activity 
(shown as % inhibition, (O), adrenochrome formation (~), and for 
malondialdehyde generated ( z~ ). From [56]. 
flow from NADH or NADPH to the respiratory agents by 
MPP +, oxyradical formation would be greatly enhanced, 
giving rise to a two-pronged assault on the integrity of the 
cell: depletion of ATP because of the blockade of oxida- 
tive phosphorylation and oxyradical damage. We have, 
therefore, undertaken to verify these important findings. 
It is known that both rotenone and the more potent 
piericidin A are bound at specific sites responsible for the 
inhibition of NADH oxidation and also at spurious sites, 
from which they can removed by washing the particles 
with bovine serum albumin (BSA), without a significant 
effect on the inhibition [55]. In the studies quoted [52,53] 
this important fact was not considered. When we removed 
the rotenone bound at the unspecific sites, extensive inhibi- 
tion of NADH oxidation remained, but 02-  generation 
ceased (Fig. 11) [56]. Further, while TPB-  greatly in- 
creases the inhibition of NADH oxidation by MPP + in 
experiments of short duration, it failed to increase superox- 
ide formation. Specifically bound piericidin A also failed 
to elicit superoxide formation (Fig. 12), as was also found 
with rotenone. These and other evidence [56] clearly sug- 
gest that the formation of superoxide is not directly related 
to the inhibition of electron flux from NADH dehydro- 
genase to the respiratory chain but is more likely to occur 
at other sites. In contrast, the studies of Glinn et al. [57] 
and ours [56] have confirmed that Complex I is involved in 
the generation of the free radicals responsible for lipid 
peroxidation. As shown in Fig. 12, removal of unspecifi- 
cally bound piericidin does not affect lipid peroxidation i  
submitochondrial particles. Glinn et al. [57] have also 
published strong evidence suggesting that lipid peroxida- 
tion also occurs as a result of succinate oxidation via 
Complex II. 
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